Why the study?
Is transapical TAVI cost-effective compared to high-risk AVR and medical management in high-risk patients?
Is transapical TAVI cost-effective compared to high-risk AVR and medical management in high-risk patients?
In a decision-analytic model, transapical TAVI was cost-effective compared to medical management but did not meet incremental cost-effectiveness criteria relative to high-risk surgical AVR.
No takes yet. Share an insight, caveat, or question.
AVR dominates transapical TAVI on incremental cost-effectiveness; reinforces surgical preference in high-risk aortic stenosis models.
Gada et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: